S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Price, News & Analysis

$4.54
+0.32 (+7.58%)
(As of 03/28/2024 ET)
Today's Range
$4.22
$4.67
50-Day Range
$4.17
$6.08
52-Week Range
$3.66
$14.50
Volume
4,771 shs
Average Volume
25,000 shs
Market Capitalization
$23.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

SAB Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
120.3% Upside
$10.00 Price Target
Short Interest
Healthy
0.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of SAB Biotherapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.64) to ($2.96) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars

Medical Sector

335th out of 939 stocks

Biological Products, Except Diagnostic Industry

49th out of 158 stocks

SABS stock logo

About SAB Biotherapeutics Stock (NASDAQ:SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABS Stock Price History

SABS Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
SAB Biotherapeutics Names Samuel Reich Chief Executive
SAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEO
SAB Biotherapeutics Announces Executive Leadership Change
SAB Biotherapeutics GAAP EPS of -$0.10
See More Headlines
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/21/2023
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+120.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-18,740,000.00
Net Margins
-664.68%
Pretax Margin
-664.04%

Debt

Sales & Book Value

Annual Sales
$23.90 million
Book Value
$7.22 per share

Miscellaneous

Free Float
3,874,000
Market Cap
$23.74 million
Optionable
Not Optionable
Beta
0.78
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Samuel J. Reich (Age 49)
    CEO & Executive Chairman
    Comp: $376.2k
  • Dr. Eddie Joe Sullivan Ph.D. (Age 57)
    Co-Founder, President & Director
    Comp: $430.62k
  • Ms. Christine E. Hamilton M.B.A. (Age 68)
    Co-Founder & Independent Director
    Comp: $25k
  • Dr. Alexandra Kropotova M.B.A. (Age 51)
    M.D., Executive VP & Chief Medical Officer
    Comp: $486.96k
  • Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Mr. Michael George King Jr. (Age 63)
    EVP & CFO
  • Dr. Christoph Bausch M.B.A. (Age 53)
    Ph.D., Executive VP & COO
  • Dr. Carlos N. Carillo Ph.D.
    Senior Vice President of Regulatory Affairs

SABS Stock Analysis - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SABS shares.
View SABS analyst ratings
or view top-rated stocks.

What is SAB Biotherapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12 month target prices for SAB Biotherapeutics' shares. Their SABS share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 120.3% from the stock's current price.
View analysts price targets for SABS
or view top-rated stocks among Wall Street analysts.

How have SABS shares performed in 2024?

SAB Biotherapeutics' stock was trading at $0.6875 on January 1st, 2024. Since then, SABS stock has increased by 560.4% and is now trading at $4.54.
View the best growth stocks for 2024 here
.

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our SABS earnings forecast
.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) announced its quarterly earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The business had revenue of $0.09 million for the quarter. SAB Biotherapeutics had a negative net margin of 664.68% and a negative trailing twelve-month return on equity of 120.36%.

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (175.49%), BVF Inc. IL (175.43%), Commodore Capital LP (35.02%), Vanguard Group Inc. (19.05%), Vanguard Group Inc. (19.04%) and Pathstone Holdings LLC (9.68%). Insiders that own company stock include Christine E Hamilton, Eddie Joe Sullivan, Michael King and Samuel J Reich.
View institutional ownership trends
.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SABS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners